



Regd. Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com

Corporate Identity Number: L24249MH1972PLC015544

XBLK! 1311201906280433.

Ref No: TPL PP 0925 2019

13th November, 2019

To

BSE Limited

Corporate Relationship Department,

1st Floor New Trading Ring,

Phiroze Jeejeebhoy Towers, Dalal Street, Fort,

Mumbai: 400 001.

Dear Sir / Madam,

Sub: Submission of Un-audited Financial Results for the Quarter and half year ended 30th September, 2019 Ref: Security Code No. 512101 - ISIN No.: INE331E01013.

We refer to our letter dated 4th November, 2019 on the captioned subject.

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, In this regard, we wish to inform you that the Board of Director in its meeting held today i.e. Wednesday, 13th November, 2019 has considered and approved the Un-audited Financial Results of the Company for the quarter and half year ended 30th September, 2019 duly reviewed by the Audit Committee. The said financial results, duly signed by the Director & CEO of the company and the auditor's report thereon are enclosed for your perusal and records.

The Audited financial results will be published in English and Marathi dailies newspaper on 14^{th} November, 2019, as required. Please take the same in your records.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIRECTOR & CEO

DIN: 00312369

Encl.: as above

Progue Mumbai

Factory: Plot No. 10/2, MIDC Industrial Area, Chikhloli, Ambernath (West), Dist. Thane, PIN - 421 505 MAHARASHTRA.

Tel.: 0251-268 2191 * 268 2711 | Fax: 0251-268 2192

Kanu Doshi Associates LLP

Chartered Accountants

Mumbai Address : 203, The Summit, Hanuman Road, Western Express Highway, Vile Parle (E), Mumbai - 400 057 T : 022-2615 0100 / 111 / 112 • F : 022 2615 0113

Pune Address: 123, Sohrab Hall, 21 Sassoon Road, Opp. Jehangir Hospital, Pune - 411001 • T: 020 4906 7177

E:info@kdg.co.in • W:www.kdg.co.in

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To, The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("Company")

- We have reviewed the accompanying statement of unaudited financial results of TRIOCHEM PRODUCTS LIMITED ("Company") for the quarter ended and year to date ended September 30, 2019 and the statements of assets and liabilities on that date together with notes thereon (the 'Statement') attached herewith, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time. Attention is drawn to the fact that the figures of net cash outflows for the corresponding period from April 1, 2018 to September, 30, 2018, as reported in these unaudited financial results have been approved by the Board of Directors of the Company, but have not been subjected to review. The statement is the responsibility of the Company's management and has been approved by Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind As 34"), specified under Section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/PAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India.
- We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP

Chartered Accountants

Firm Registration No: 104746WW100096

Kunal Vakharia

Partner

Membership No.: 148916

UDIN: 19148916AAAAGN92810

Place: Mumbai

Date: 13th November, 2019



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.

Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com | www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544

TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com CIN: L24249MH1972PLC015544

STAT	FATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2019						
						100000000000000000000000000000000000000	h) Except EPS
Sr.	Particulars		Quarter Ended		Half Yea	r Ended	Year Ended
No.		30-Sep-19	30-Jun-19	30-Sep-18	30-Sep-19	30-Sep-18	31-Mar-19
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue from Operations	261.76	52.60	29.94	314.36	700.66	1,235.47
	(b) Other Income	0.16	0.16	1.85	0.32	2.87	5.52
	Total Income From Operations	261.92	52.76	31.79	314.68	703.53	1,240.99
2	Expenses						
	(a) Cost of Materials Consumed	0.00		(9.69)	0.00	599.56	1,099.78
	(b) Purchase of stock in trade				-	6.00	55.60
	(c) Changes in inventories of finished goods, work-in-progress and	166.65	35.90	(4.84)	202.55	(97.31)	(311.83)
	stock-in-trade			12	UN 800 - 100		0.000 00000
	(d) Employees Benefit Expenses	19.36	15.52	16.68	34.88	34.49	71.90
	(e) Finance Costs	2.67	5.16	14.17	7.83	25.83	45.46
	(f) Depreciation and Amortisation Expenses	4.20	4.16	5.16	8.36	10.27	20.54
	(g) Other Expenditure	26.68	30.93	33.53	57.61	72.11	155.59
	Total expenses	219.56	91.67	55.01	311.23	650.95	1,137.04
3	Profit before exceptional items and tax	42.36	(38.91)	(23.22)	3.45	52.58	103.95
4	Exceptional items		8.0	5.			if
5	Profit/ (Loss) before tax	42.36	(38.91)	(23.22)	3.45	52.58	103.95
6	Tax Expense						
	(a) Current tax	2.29		(6.42)	2.29	15.75	30.75
	(b) Deferred tax	7.27	(10.78)	(1.46)	(3.51)	(4.32)	(1.10)
	Total tax expenses	9.56	(10.78)	(7.88)	(1.22)	11.43	29.65
7	Net Profit/ (Loss) for the period	32.80	(28.13)	(15.34)	4.67	41.15	74.30
8	Other Comprehensive Income (Net of Taxes)						
	(A)(i). Items that will be reclassified to profit or loss			•	•	•	
	(ii). Income tax relating to items that will be reclassified to profit or loss	•		•			Ē
	(B)(i). Item that will not be reclassified to profit or loss	(0.30)	0.01	(0.57)	(0.29)	(0.95)	0.02
	(ii). Income tax relating to items that will not be reclassified to profit or loss	0.09	(0.01)	0.15	0.08	0.25	(0.01)
	Total other Comprehensive Income (net of taxes)	(0.21)		(0.42)	(0.21)	(0.70)	0.01
9	Total Comprehensive Income for the period	32.59	(28.13)	(15.76)	4.46	40.45	74.31
10	Paid-up equity share capital (Face Value of ₹ 10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
11	Other equity as per Balance Sheet of previous accounting year						853.07
12	Earnings per equity share (EPS) (of Rs.10/- each) (not annualised)						
	Basic / Diluted EPS (in Rs.)	13.39	(11.48)	(6.26)	1.90	16.80	30.33







9----

Page 1 of 4



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.

Tel.: 00 91 (22) 4082 8100 I Fax: 00 91 (22) 4082 8181 I E-mail: info@amphray.com I www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544

S	STATEMENT OF ASSETS AND LIABILITIES AS AT 30th SEPTEM	BER, 2019	
	Particulars	As at	As at
		30-Sep-19	31-Mar-19
		(Unaudited)	(Audited)
A A	ASSETS		
N	Non- Current Assets		
((a) Property, plant and equipment	105.62	113.78
((b) Investment property	8.32	8.52
((c) Other intangible assets		
(d) Financial assets		
	(i) Other financial assets	7.32	7.32
((e) Other non current Assets	1.36	1.15
s	Sub Total - Non- Current Assets	122.62	130.77
C	Current Assets		
(a) Inventories	754.89	957.44
(b) Financial Assets		
18	(i) Trade receivable	*	333.01
	(ii) Cash and cash equivalents	81.06	24.90
	(iii) Other financial assets	0.31	0.54
(c) Other tax assets (net)	27.58	8.30
(c) Other current assets	484.64	60.07
S	Sub Total - Current Assets	1,348.48	1,384.32
T	TOTAL ASSETS	1,471.10	1,515.09
ВЕ	EQUITY AND LIABILITIES		
E	Equity		
(a) Equity share capital	24.50	24.50
(b) Other equity	857.52	853.07
S	Sub Total - Shareholder's fund	882.02	877.57
L	iabilities		
(a) Non Current Liabilities		
122	(a) Deferred tax liabilities (Net)	8.25	11.83
0	b) Current Liabilities		
	(a) Financial liabilities		
	(i) Borrowing	540.28	579.42
	(ii) Trade payables	20.65	34.13
	(b) Other financial liabilities	5.73	2.05
	(c) Other current liabilities	4.98	1.24
	(d) Provisions	9.19	8.85
	(e) Current tax liabilities (Net)		=
s	oub Total - Liabilities	589.08	637.52
т	OTAL EQUITY AND LIABILITIES	1,471.10	1,515.09





9

Page 2 of 4



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.

Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com | www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544

	CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th SEPTEMBER, 2019				
	Particulars Particulars	Half Yea	ar Ended		
		30-Sep-19	30-Sep-18		
		(Unaudited)	(Unaudited)		
A	CASH FLOW FROM OPERATING ACTIVITIES				
	Net Profit before tax and Extraordinary Items	3.45	52.58		
	Adjustment for:				
	Depreciation / Amortisation	8.36	10.27		
	Interest Income	(0.32)	(0.28)		
	Reclassification of remeasurement of employee benefits	(0.29)	(0.94)		
	Interest Expenses	7.83	25.83		
	Net gain on sale of Asset		(0.06)		
	Investment Expenses	0.04	0.05		
	Sundry balance Off	0.00	0.00		
	Operating Profit before Working Capital Changes	19.07	87.45		
	Adjustments for Working Capital Changes				
	Increase/Decrease in Assets	(424.77)	(26.34)		
	Changes in Inventories	202.55	(318.41)		
	Increase/Decrease Trade Receivable	333.01	(45.92)		
	Increase/Decrease in other financial and non-financial assets				
	Increase/Decrease Trade payables	(13.48)	(51.13)		
	Increase/Decrease in other financial and non-financial liabilities	3.68	22.59		
	Increase/Decrease in Liabilities	3.74	1.67		
	Changes in Provision	0.34	0.35		
	Cash Generated from Operations	124.14	(329.74)		
	Direct taxes paid / (refund)				
	Advance tax	(22.50)	(18.50)		
	TDS paid				
	Self Assessment tax	•	(46.61)		
	Interest on income tax				
	Refund received	0.99	*		
	Net Cash from Operating Activities	102.63	(394.85)		
В	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of Fixed Assets including Capital Work in Progress	•	•		
	Sales of Fixed Assets		0.15		
	Investment Expenses	(0.04)	(0.05)		
	Interest Received	0.54	0.56		
	Net Cash Used in Investing Activity	0.50	0.66		
С	CASH FLOW FROM FINANCING ACTIVITIES				
	Net (Decrease)/ Increase in Short Term Borrowings	(39.14)	335.61		
	Interest Paid	(7.83)	(25.83)		
	Net Cash Used in Financing Activity	(46.97)	309.78		
	NET CHANGES IN CASH & CASH EQUIVALENTS (A+B+C)	56.16	(84.41)		
	OPENING BALANCE OF CASH & CASH EQUIVALENTS	24.90	91.91		
	CLOSING BALANCE OF CASH & CASH EQUIVALENTS	81.06	7.51		
		56.16	(84.41)		
		70.10	(01.11)		



9

MUNICAL E

Page 3 of 4

Factory: Plot No. 10/2, MIDC Industrial Area, Morivali, Ambernath (West), Dist. Thane, PIN - 421 501 MAHARASHTRA.

Tel.: 0251-268 2191 * 268 2711 | Fax: 0251-268 2192 | Email: info@amphray.com



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.

Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com | www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544

Notes:

- 1) The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th November 2019. The Statutory auditors of the company has carried out a limited review of aforesaid results.
- 2) The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019. The effect on adoption of Ind AS 116 on the financial results is insignificant.
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals the disclosure requirement of Indian Accounting Standard (IND AS-108) Segment Reporting" is not applicable.
- 4) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

) — _____

RAMU S. DEORA DIRECTOR & CEO DIN: 00312369

Place: Mumbai

Dated: 13th November, 2019







MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Read, Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.

Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com | www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544

TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com

CIN: L24249MH1972PLC015544

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2019

1	Re	in	lakh) F	vce	nt	EP

Sr.	Particulars Particulars		Quarter Ended		Half Yea	r Ended	Year Ended
No.		30-Sep-19	30-Jun-19	30-Sep-18	30-Sep-19	30-Sep-18	31-Mar-19
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Net Operating Income	261.92	52.76	31.79	314.68	703.53	1,240.99
2	Profit / (Loss) for the period (before Interest, Depreciation, Taxes, Exceptional and / or Extraordinary items)	49.24	(29.59)	(3.89)	19.65	88.68	169.95
3	Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	42.36	(38.91)	(23.22)	3.45	52.58	103.95
4	Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	32.80	(28.13)	(15.34)	4.67	41.15	74.30
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(0.21)	•	(0.42)	(0.21)	(0.70)	0.01
5	Equity share capital (Face value of Rs.10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
7	Reserve (excluding Revaluation Reserves as shown in the Balance Sheet of previous year)						853.07
	Earnings per equity share (EPS) (of Rs. 10/- each) (for continuing and discontinued operations)						
	a) Baisc (not annualized)	13.39	(11.48)	(6.26)	1.90	16.80	30.33
	b) Diluted (not ammualized)	13.39	(11.48)	(6.26)	1.90	16.80	30.33

Notes:

- 1) The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th November 2019. The Statutory auditors of the company has carried out a limited review of aforesaid results
- 2) The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019. The effect on adoption of Ind AS 116 on the financial results is insignificant.
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals the disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- 4) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
- 5) The above is an extract of the detailed format of quarterly and half year ended financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of the quarterly and half year ened financial results are available on the on the Stock Exchange and the Company namely www.bseindia.com and www.triochemproducts.com

FOR TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA DIRECTOR & CEO

DIN: 00312369

Place: Mumbai Dated: 13th November, 2019

Progues of Mumbal

BSE LTD ACKNOWLEDGEMENT

Acknowledgement No : 1311201906280433 Date & Time : 13/11/2019 18:28:04

Scrip Code : 512101

Entity Name : Triochem Products Limited

Compliance Type : Regulation 33 - Financial Results

Quarter / Period : 30/09/2019

Mode : E-Filing

General information about company					
Scrip code	Scrip code 512101				
NSE Symbol					
MSEI Symbol					
ISIN*	INE331E01013				
Name of company	Triochem Products Limited				
Type of company					
Class of security	Equity				
Date of start of financial year	01-04-2019				
Date of end of financial year	31-03-2020				
Date of board meeting when results were approved	13-11-2019				
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	04-11-2019				
Description of presentation currency	INR				
Level of rounding used in financial results	Lakhs				
Reporting Quarter	Half yearly				
Nature of report standalone or consolidated	Standalone				
Whether results are audited or unaudited	Unaudited				
Segment Reporting	Single segment				
Description of single segment	The Company operates in single segment only, i.e. chemical and pharmaceuticals the disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.				
Start date and time of board meeting	13-11-2019 16:00				
End date and time of board meeting	13-11-2019 17:10				
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable				

	Financial	Results - Ind-AS	
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Α	Date of start of reporting period	01-07-2019	01-04-2019
В	Date of end of reporting period	30-09-2019	30-09-2019
С	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Con months ended, in such case zero shall be inserted in the		ny has no figures for 3 months / 6
1	Income		
	Revenue from operations	261.76	314.36
	Other income	0.16	0.32
	Total income	261.92	314.68
2	Expenses		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in- progress and stock-in-trade	166.65	202.55
(d)	Employee benefit expense	19.36	34.88
(e)	Finance costs	2.67	7.83
(f)	Depreciation, depletion and amortisation expense	4.2	8.36
(f)	Other Expenses		
1	Other Expenses	26.68	57.61
10			
	Total other expenses	26.68	57.61
	Total expenses	219.56	311.23

	Financial Results –	Ind-AS	
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Α	Date of start of reporting period	01-07-2019	01-04-2019
В	Date of end of reporting period	30-09-2019	30-09-2019
С	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Re months ended, in such case zero shall be inserted in the said colum		no figures for 3 months / 6
3	Total profit before exceptional items and tax	42.36	3.45
4	Exceptional items	0	0
5	Total profit before tax	42.36	3.45
7	Tax expense		
8	Current tax	2.29	2.29
9	Deferred tax	7.27	-3.51
10	Total tax expenses	9.56	-1.22
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	32.8	4.67
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	32.8	4.67

	Financ	ial Results – Ind-AS	
	Particulars	3 months/ 6 month ended (dd- mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2019	01-04-2019
В	Date of end of reporting period	30-09-2019	30-09-2019
С	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit a	and loss	
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	-0.09	-0.08
3	Amount of items that will be reclassified to profit and	loss	
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.3	0.29
5	Total Other comprehensive income	-0.21	-0.21

	Financial Resu	lts – Ind-AS	
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Α	Date of start of reporting period	01-07-2019	01-04-2019
В	Date of end of reporting period	30-09-2019	30-09-2019
С	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidate months ended, in such case zero shall be inserted in the said c		has no figures for 3 months / 6
23	Total Comprehensive Income for the period	32.59	4.46
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	C
26	Details of equity share capital		
	Paid-up equity share capital	24.5	24.5
	Face value of equity share capital	10	10
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	13.9	1.9
	Diluted earnings (loss) per share from continuing operations	13.9	1.9
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	13.9	1.9
	Diluted earnings (loss) per share from continuing and discontinued operations	13.9	1.9
30	Debt equity ratio		A
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	Disclosure of notes on financial results	Textual Information(1)	

	Text Block				
Textual Information(1)	1) The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th November 2019. The Statutory auditors of the company has carried out a limited review of aforesaid results. 2) The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019. The effect on adoption of Ind AS 116 on the financial results is insignificant. 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals the disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable. 4) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.				

	Particulars	Half year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2019
	Date of end of reporting period	30-09-2019
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
T	Assets	
1	Non-current assets	
	Property, plant and equipment	105.62
	Capital work-in-progress	
	Investment property	8.33
	Goodwill	
	Other intangible assets	(
	Intangible assets under development	(
	Biological assets other than bearer plants	(
	Investments accounted for using equity method	
	Non-current financial assets	
	Non-current investments	
	Trade receivables, non-current	(
	Loans, non-current	
	Other non-current financial assets	7.32
	Total non-current financial assets	7.32
	Deferred tax assets (net)	
	Other non-current assets	1.30
	Total non-current assets	122.62
2	Current assets	
	Inventories	754.89
	Current financial asset	
	Current investments	(
	Trade receivables, current	(
	Cash and cash equivalents	0.47
П	Bank balance other than cash and cash equivalents	80.59
	Loans, current	(
	Other current financial assets	0.31
	Total current financial assets	81.37
	Current tax assets (net)	27.58
	Other current assets	484.64
	Total current assets	1348.48

Particulars	Half year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2019
Date of end of reporting period	30-09-2019
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Standalone
Non-current assets classified as held for sale	0
Regulatory deferral account debit balances and related deferred tax Assets	0
Total assets	1471.1
Equity and liabilities	
Equity	
Equity attributable to owners of parent	
Equity share capital	24.5
Other equity	857.52
Total equity attributable to owners of parent	882.02
Non controlling interest	
Total equity	882.02
Liabilities	
Non-current liabilities	
Non-current financial liabilities	
Borrowings, non-current	540.28
Trade payables, non-current	20.65
Other non-current financial liabilities	
Total non-current financial liabilities	560.93
Provisions, non-current	(
Deferred tax liabilities (net)	8.25
Deferred government grants, Non-current	
Other non-current liabilities	
Total non-current liabilities	569.18
Current liabilities	
Current financial liabilities	
Borrowings, current	
Trade payables, current	
Other current financial liabilities	5.73
Total current financial liabilities	5.73
Other current liabilities	4.98
Provisions, current	9.19
Current tax liabilities (Net)	7.1.2
Deferred government grants, Current Total current liabilities	19.5
	19.5
Liabilities directly associated with assets in disposal group classified as held for sale	
Regulatory deferral account credit balances and related deferred tax liability Total liabilities	589.00
Total equity and liabilites	Textual Information(1)

	Text Block			
Textual Information(1)	1) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.			

	Particulars	3 months/ 6 month ended (dd- mm-yyyy)	Year to date figures for current period ended (dd mm-yyyy)		
	Date of start of reporting period	01-07-2019	01-04-2019		
	Date of end of reporting period	30-09-2019	30-09-2019		
	Whether accounts are audited or unaudited				
	Nature of report standalone or consolidated	Standalone	Standalone		
1	Segment Revenue (Income)				
	(net sale/income from each segment should be disclosed)				
	Total Segment Revenue				
	Less: Inter segment revenue				
	Revenue from operations				
2	Segment Result				
	Profit (+) / Loss (-) before tax and interest from each segment				
	Total Profit before tax				
	i. Finance cost				
	ii. Other Unallocable Expenditure net off Unallocable income				
	Profit before tax				
3	(Segment Asset - Segment Liabilities)				
	Segment Asset				
	Total Segment Asset				
	Un-allocable Assets				
	Net Segment Asset				
4	Segment Liabilities				
	Segment Liabilities				
	Total Segment Liabilities				
Ī	Un-allocable Liabilities				
	Net Segment Liabilities				
	Disclosure of notes on segments				